• Does Anti–Tumor Necrosis Factor ? Therapy...

    Added On : 19th November 2011

    Does Anti–Tumor Necrosis Factor ? Therapy Increase the Risk for Serious Infection?

    In this large cohort study, unlike in most of the previous studies, researchers found no increased risk for serious infections with TNF antagonists.

  • TP53 and Basal Cell Carcinomas

    Added On : 2nd December 2011

    Researchers identified a variant that confers susceptibility to BCCs and other cancers.

  • Dermatopathology Workforce in the U.S...

    Added On : 15th December 2011

    Dermatopathology Workforce in the U.S.: An Overview

    Who practices dermatopathology, how happy are they, and how can we assure a continuing presence at sufficiency in academia?

    To characterize the dermatopathology workforce in the U.S., these authors sent a questionnaire to all 913 Fellow members of the American Society of Dermatopathology (ASDP). The objectives were to collect data about current practice and future plans, identify characteristics of academic practitioners, and explore satisfaction regarding fellowship training.

  • Behind the Numbers: Number Needed to Screen

    Added On : 28th December 2011

    Dr. Joel Gelfand elucidates the concept of number needed to screen in "Behind the Numbers", a new Journal Watch Dermatology feature aimed at clarifying issues in epidemiologic design and biostatistics.

  • Granulomatous Processes and Clonality...

    Added On : 10th January 2012

    Granulomatous Processes and Clonality: PCR Evaluation of T-Cell Rearrangement for Diagnosis

    Analysis of T-cell clonality is useful for differentiating sarcoidosis and primary granuloma annulare from granulomatous CTCLs.

  • Stem Cells on the Clock: Circadian Rhythm...

    Added On : 24th January 2012

    Stem Cells on the Clock: Circadian Rhythm Proteins Regulate Epidermal Stem Cells

    Investigators found an association between expression of genes associated with stem cell function and expression of circadian rhythm genes.

  • Basal Cell Carcinoma at a Young Age...

    Added On : 7th February 2012

    Basal Cell Carcinoma at a Young Age: Another Consequence of Tanning Beds

    Tanning bed users younger than 40 developed early-onset BCCs significantly more often than nonusers.

  • What Is the Optimal Frequency...

    Added On : 21st February 2012

    What Is the Optimal Frequency of Postmelanoma Follow-Up?

    A new schedule would reduce the number of follow-up visits.

  • Vemurafenib for Previously Treated Melanomas

    Added On : 5th March 2012

    Vemurafenib induced clinical response in more than half of patients with previously treated BRAF V600E–mutant metastatic melanoma.

    Vemurafenib significantly improved survival at 6 months in patients with metastatic melanoma in the BRIM-3 trial, but its effectiveness in patients previously treated with other drugs and its longer-term efficacy were undetermined. Investigators conducted this updated, phase 2 trial of vemurafenib in 132 patients with BRAF V600–mutant metastatic melanoma who had received other prior treatment.

  • A New Medication for Treatment of Actinic Keratoses

    Added On : 19th March 2012

    Ingenol mebutate gel was significantly more effective than vehicle alone.

    Actinic keratoses (AKs) are extremely common lesions that affect nearly 40 million individuals in the United States alone and many more worldwide. Conversion rates of AKs to nonmelanoma skin cancers are estimated to range from 6% to 10% over a 10-year period. Field therapy of the entire area of sun-damaged skin is frequently performed in patients with extensive AKs. Although highly effective, most forms of field therapy require prolonged treatment and cause a protracted irritant reaction, sometimes quite strong. Ingenol mebutate, the active ingredient of sap of Euphorbia peplus, has been in long use in Australia for many skin conditions. These investigators conducted two manufacturer-supported trials of the safety and efficacy of a 0.015% concentrate of ingenol mebutate gel for AKs of the face and scalp in 547 patients with extensive actinic damage and multiple AKs.